In previously treated patients with NSCLC (e.g., PD-L1-positive advanced NSCLC and advanced non-squamous NSCLC), however, the therapeutic effect of immune checkpoint inhibitors was limited, with the response rate remaining at ~20% [2,4]. Here, CD274 is linked to non-small cell lung carcinoma.